Skip to main content
. 2010 Nov 30;103(12):1852–1857. doi: 10.1038/sj.bjc.6605970

Figure 3.

Figure 3

Kaplan–Meier analysis of stage 2 and 3 colon cancer patients stratified by clinical staging and the 163-gene prognostic signature. Risk-group predictions for those patients who were part of the training series (n=144) were determined by cross-validation analysis. The final 163-gene classifier was then applied to the independent analysis series (n=60) of patients, who were not involved in the gene selection or algorithm development process. P-values generated by the log rank test.